Loading…
Protecting Patient Access to Cancer and Complex Therapies Act
Legislative Progress
Momentum (last 30 days)
10
score
0 actions · 5 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (28)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Medicare/Medicaid
HR 4299 - The Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · third_quarter · Health Issues
HR 4299 - The Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · third_quarter · Medicare/Medicaid
Legislation to stop restrictions to practices mailing oral drugs (HR 2484) Technical fix to the Inflation Reduction Act regarding drug negotiation (HR 4299) Increase in Medicare payments to physicians and an inflation update Legislative fixes to the 340B Drug Purchasing Program Site neutral payments to hospitals Misc legislation to stop pharmacy benefit manager patient abuses and low-ball reimbursement Prior authorization and step therapy issues Medicare physician fee schedule payment cuts to radiation therapy
Client expense: $265,800 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medicare/Medicaid
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; Health Data, Artificial Intelligence, Interoperability and ePrior Authorization; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Client expense: $610,000 · Firm income: Not reported
2026 · third_quarter · Health Issues
Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act for Fiscal Year 2027 (NDAA - H.R.8800/S.4784) Supply Chain Resiliency Most Favored Nation drug pricing proposals Direct to consumer pharmacy proposals CMS FY 2026 Medicare Part B Physician Fee Schedule Rule Break Up Big Medicine Act (S. 3822) Stop Corporate Take Over of Physicians Act (H.R.10444/S.5419) Role and value of community specialty physicians and Management Services Organizations (MSOs) NIH Restructuring/National Eye Institute Pandemic and All-Hazards Preparedness/Protecting Americans from All Hazards Preparedness Act (PAHPA) Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299)
Client expense: $405,804 · Firm income: Not reported
| Republican |
| NE |
| Andy Harris | Republican | MD |
| August Pfluger | Republican | TX |
| Beth Van Duyne | Republican | TX |
| Blake D. Moore | Republican | UT |
| Brian Babin | Republican | TX |
| Brian K. Fitzpatrick | Republican | PA |
| Carol D. Miller | Republican | WV |
| Claudia Tenney | Republican | NY |
| Dan Crenshaw | Republican | TX |
| Darin LaHood | Republican | IL |
| David Kustoff | Republican | TN |
| Donald G. Davis | Democratic | NC |
| Earl L. "Buddy" Carter | Republican | GA |
| Eric Sorensen | Democratic | IL |
| Gus M. Bilirakis | Republican | FL |
| Henry Cuellar | Democratic | TX |
| Herbert C. Conaway, Jr. | Democratic | NJ |
| Jake Ellzey | Republican | TX |
| Janelle S. Bynum | Democratic | OR |
| Jared Moskowitz | Democratic | FL |
| Jefferson Van Drew | Republican | NJ |
| John Joyce | Republican | PA |
| Josh Gottheimer | Democratic | NJ |
| Juan Ciscomani | Republican | AZ |
| Kevin Hern | Republican | OK |
| Lance Gooden | Republican | TX |
| Lloyd Smucker | Republican | PA |
| Marc A. Veasey | Democratic | TX |
| Mariannette Miller-Meeks | Republican | IA |
| Mark Alford | Republican | MO |
| Max L. Miller | Republican | OH |
| Michelle Fischbach | Republican | MN |
| Mike Carey | Republican | OH |
| Mike Flood | Republican | NE |
| Mike Kelly | Republican | PA |
| Mike Kennedy | Republican | UT |
| Nathaniel Moran | Republican | TX |
| Neal P. Dunn | Republican | FL |
| Nicholas A. Langworthy | Republican | NY |
| Nicole Malliotakis | Republican | NY |
| Pat Harrigan | Republican | NC |
| Randy K. Weber, Sr. | Republican | TX |
| Raul Ruiz | Democratic | CA |
| Richard McCormick | Republican | GA |
| Russell Fry | Republican | SC |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Scott H. Peters | Democratic | CA |
| Sharice Davids | Democratic | KS |
| Thomas H. Kean, Jr. | Republican | NJ |
| Thomas R. Suozzi | Democratic | NY |
| Troy Balderson | Republican | OH |
| Vicente Gonzalez | Democratic | TX |
| Zoe Lofgren | Democratic | CA |
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Medicare/Medicaid
Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/ Main Street Pharmacy Access Act (H.R. 3164)/ Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R 4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and mitigating generic drug shortages CMS FY 2026 Medicare Part B Physician Fee Schedule Medicare physician reimbursement CY2026 Medicare Physician Fee Schedule Rule CMS FY 2027 Medicare Physician Fee Schedule Distributor bona fide service fees Patients First Act of 2026 (H.R.9693)
Client expense: $405,804 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Health Issues
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)
Client expense: $3,050,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
H.R. 2484, Seniors Access to Critical Medications Act; Issues related to the extension of telehealth services; Issues related to site neutral payments; Issues related to 2024 Physician Fee Schedule and physician payment reform; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to in-office dispensing of medication regulations; H.R. 8163/S. 5180, Provider Reimbursement Stability Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Support for H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 1672, Maintaining Investments in New Innovation Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to prescription drugs; Issues related to Senate Finance Dear Colleague process; Issues related to the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the Orphan Cures Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA); Issues related to Most Favored Nation (MFN)
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related to Senate Finance Dear Colleague process; H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act H.R. 8630, The Protecting Equal Access to Thyroid Act of 2026 Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to FDA communications
Client expense: $1,050,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Health Issues
- H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act, regarding all provisions - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act, regarding all provisions - S.1399 / H.R. 6197, the Health Tech Investment Act, regarding all provisions - H.R. 3521, the Clinical Trial Modernization Act, regarding all provisions - H.R. 3006 / S.1776, the Medicare Beneficiary Co-Pay Fairness Act, regarding all provisions - H.R. 3514, the Improving Seniors Timely Access to Care Act of 2025, regarding all provisions - H.R. 6549, the VA Contracting and Procurement Act, regarding all provisions - H.R. 5509 / S. 2903, Safe Step Act, regarding all provisions - H.R. 5256, 340B ACCESS Act, regarding all provisions - H.R. 7391, Community Health Center Drug Pricing Protection Act, regarding all provisions - H.R. 3953 / S. 1874 Title VIII Nursing Workforce Reauthorization Act, regarding all provisions Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B and 340B Rebate Pilot - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - MFN - Foreign Reference Pricing - CMS Outpatient Prospective Payment System rule - peripheral artery disease (PAD) - PBM and Insurer Reforms
Client expense: $2,220,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Health Issues
Monitor federal issues and legislation associated with health care policy. Monitor federal and legislative activity related to Medicare reimbursement. Monitor federal and legislative activity related to drug pricing. Dr. Lorna Breen Healthcare Provider Protection Reauthorization Act (HR 929 / S 266) Medicare Patient Access and Practice Stabilization Act (HR 879/ S.1640) Reducing Medically Unnecessary Delays in Care Act (HR 2433) Resident Education Deferred Interest (REDI) Act (HR 2028 / S 942) Help Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timely Access to Care Act (S. 1816/HR. 3514) One Big Beautiful Bill Act (HR. 1) Safe Step Act (HR 5509/S. 668) Patient Access to Autoimmune Treatment, PAAT, Act (HR. 5467) Protecting Patient Access to Cancer and Complex Therapies Act (HR 4299) PBM Reform Act of 2025 (HR 4317) Workforce Mobility Act (S.2031) Specialty Physicians Advancing Rural Care, SPARC, Act (H.R 4681/S. 1380) Connect for Health Act of 2025 (HR 2406/S. 1261) Telehealth Modernization Act (HR 5081/S 2709) House Concurrent Res. 14 establishing congressional budget for FY2025 Department of Labor, HHS, and Education Appropriations Act (S. 2587) Department of Defense Appropriations Act (HR 4016/S. 2572) Seniors Deserve SMARTER Care Act (HR 5940) A bill to require private plans to provide for e-prior auth for drugs (S. 4349) Patient Access to Higher Quality Health Care Act (HR 4002) Biosimilar Red Tape Elimination Act (HR 5526/S. 1954) Medical Foods and Formulas Access Act (HR 5684) Physician Led and Rural Access to Quality Care Act (HR 2191/S. 1390) Claims Data Act, H.R. 4331 Rural Residency Planning and development Act of 2025, H.R. 6468 To exempt H-1B health care workers from the restriction under the Presidential Proclamation entitled "Restriction on Entry of Certain Nonimmigrant Workers", and for other purposes, H.R. 7961 Provider Reimbursement Stability Act, H.R. 8163 PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act, S.3549 Chronic Care Management Act of 2026ﾠHR 8261 Prior Authorization Reform for Autoimmune & Blood Disorders ActﾠHR 9192 Patient Access to Autoimmune Treatments ActﾠHR 5467 Patients First Act H.R. 9693 Expedited Access to Biosimilars Act H.R. 9661/ S. 1414 Protecting Approved Care Act H.R. 10394 Doctors Not AI Act of 2026 H.R. 10210 Protecting Patients from Automatic Denials Act H.R. 9734
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medicare/Medicaid
Monitor federal issues and legislation associated with health care policy. Monitor federal and legislative activity related to Medicare reimbursement. Monitor federal and legislative activity related to drug pricing. Dr. Lorna Breen Healthcare Provider Protection Reauthorization Act (HR 929 / S 266) Medicare Patient Access and Practice Stabilization Act (HR 879/ S.1640) Reducing Medically Unnecessary Delays in Care Act (HR 2433) Resident Education Deferred Interest (REDI) Act (HR 2028 / S 942) Help Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timely Access to Care Act (S. 1816/HR. 3514) One Big Beautiful Bill Act (HR. 1) Safe Step Act (HR 5509/S. 668) Patient Access to Autoimmune Treatment, PAAT, Act (HR. 5467) Protecting Patient Access to Cancer and Complex Therapies Act (HR 4299) PBM Reform Act of 2025 (HR 4317) Workforce Mobility Act (S.2031) Specialty Physicians Advancing Rural Care, SPARC, Act (H.R 4681/S. 1380) Connect for Health Act of 2025 (HR 2406/S. 1261) Telehealth Modernization Act (HR 5081/S 2709) House Concurrent Res. 14 establishing congressional budget for FY2025 Department of Labor, HHS, and Education Appropriations Act (S. 2587) Department of Defense Appropriations Act (HR 4016/S. 2572) Seniors Deserve SMARTER Care Act (HR 5940) A bill to require private plans to provide for e-prior auth for drugs (S. 4349) Patient Access to Higher Quality Health Care Act (HR 4002) Biosimilar Red Tape Elimination Act (HR 5526/S. 1954) Medical Foods and Formulas Access Act (HR 5684) Physician Led and Rural Access to Quality Care Act (HR 2191/S. 1390) Claims Data Act, H.R. 4331 Rural Residency Planning and development Act of 2025, H.R. 6468 To exempt H-1B health care workers from the restriction under the Presidential Proclamation entitled "Restriction on Entry of Certain Nonimmigrant Workers", and for other purposes, H.R. 7961 Provider Reimbursement Stability Act, H.R. 8163 PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act, S.3549 Chronic Care Management Act of 2026ﾠHR 8261 Prior Authorization Reform for Autoimmune & Blood Disorders ActﾠHR 9192 Patient Access to Autoimmune Treatments ActﾠHR 5467 Patients First Act H.R. 9693 Expedited Access to Biosimilars Act H.R. 9661/ S. 1414 Protecting Approved Care Act H.R. 10394 Doctors Not AI Act of 2026 H.R. 10210 Protecting Patients from Automatic Denials Act H.R. 9734
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Budget/Appropriations
Monitor federal issues and legislation associated with health care policy. Monitor federal and legislative activity related to Medicare reimbursement. Monitor federal and legislative activity related to drug pricing. Dr. Lorna Breen Healthcare Provider Protection Reauthorization Act (HR 929 / S 266) Medicare Patient Access and Practice Stabilization Act (HR 879/ S.1640) Reducing Medically Unnecessary Delays in Care Act (HR 2433) Resident Education Deferred Interest (REDI) Act (HR 2028 / S 942) Help Ensure Lower Patient (HELP) Copays Act (S. 864) Patients Before Middlemen Act (S. 882) PBM Transparency Act (S. 526) Prescription Pricing for the People Act (S. 527) Conrad State 30 and Physician Access Reauthorization Act (HR 1585 / S 709) Resident Physician Shortage Reduction Act (HR.3890/S. 2439) Improving Seniors Timely Access to Care Act (S. 1816/HR. 3514) One Big Beautiful Bill Act (HR. 1) Safe Step Act (HR 5509/S. 668) Patient Access to Autoimmune Treatment, PAAT, Act (HR. 5467) Protecting Patient Access to Cancer and Complex Therapies Act (HR 4299) PBM Reform Act of 2025 (HR 4317) Workforce Mobility Act (S.2031) Specialty Physicians Advancing Rural Care, SPARC, Act (H.R 4681/S. 1380) Connect for Health Act of 2025 (HR 2406/S. 1261) Telehealth Modernization Act (HR 5081/S 2709) House Concurrent Res. 14 establishing congressional budget for FY2025 Department of Labor, HHS, and Education Appropriations Act (S. 2587) Department of Defense Appropriations Act (HR 4016/S. 2572) Seniors Deserve SMARTER Care Act (HR 5940) A bill to require private plans to provide for e-prior auth for drugs (S. 4349) Patient Access to Higher Quality Health Care Act (HR 4002) Biosimilar Red Tape Elimination Act (HR 5526/S. 1954) Medical Foods and Formulas Access Act (HR 5684) Physician Led and Rural Access to Quality Care Act (HR 2191/S. 1390) Claims Data Act, H.R. 4331 Rural Residency Planning and development Act of 2025, H.R. 6468 To exempt H-1B health care workers from the restriction under the Presidential Proclamation entitled "Restriction on Entry of Certain Nonimmigrant Workers", and for other purposes, H.R. 7961 Provider Reimbursement Stability Act, H.R. 8163 PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act, S.3549 Chronic Care Management Act of 2026ﾠHR 8261 Prior Authorization Reform for Autoimmune & Blood Disorders ActﾠHR 9192 Patient Access to Autoimmune Treatments ActﾠHR 5467 Patients First Act H.R. 9693 Expedited Access to Biosimilars Act H.R. 9661/ S. 1414 Protecting Approved Care Act H.R. 10394 Doctors Not AI Act of 2026 H.R. 10210 Protecting Patients from Automatic Denials Act H.R. 9734
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Issues related to drug pricing, bona fide service fees, pharmacies, provider status, biosimilars, cell and gene therapy, food is medicine, pharmacy services administrative organizations; Issues related to provider reimbursement, Medicare and Medicaid, workforce shortages, and product shortages; Issues related to Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS), competitive bidding, reimbursement to home healthcare agencies, H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 5031/S. 3159, Preserving Patient Access to Long-Term Care Pharmacies Act; H.R. 3164, Ensuring Community Access to Pharmacist Services Act; S. 2426, Equitable Community Access to Pharmacist Services Act, Education around issues facing independent physicians, including, S.3822, the Break Up Big Medicine Act, and H.R. 10444, Stop Corporate Takeovers of Physicians Act of 2026.
Client expense: $400,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Issues relating to HR 4299 and other heath issues.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to HR 4299
Client expense: Not reported · Firm income: $130,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Medicare/Medicaid
Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain; HR4299, Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
H.R.1 492 , S. 832, EPIC Act of 2025, all pharmaceutical related provisions H.R. 7837 Most Favored Patient Act f 2026, all pharmaceutical related provisions H.R. 4299 Protecting Patient Access to Cancer & Complex Therapies Act, all pharmaceutical related provisions H.R. 6609 Pharmacists Fight Back in Medicare and Medicaid Act, all pharmaceutical related provisions P.L. 117-169 Inflation Reduction Act, all pharmaceutical related provisions IRA: Discussions on reform (non-H.R. 4299, e.g., Orphan Cures change, biosimilars, etc) IRA: Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Medicare: Proposals enhance patient access (e.g., protected classes, telehealth, coverage) Medicare: Proposals related to payment proposals (e.g., Part D, Part B, ASP, transparency) Medicaid: Proposals related to access or pricing GLOBE CMMI Model Executive Order
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
340B S.46 - Health Care Affordability Act of 2025 Safe Step Act H.R.5509 S.864 - HELP Copays Act PBM Reform Act of 2025 PAAT Act "Patient Access to Autoimmune Treatments Act" Ensuring Patient Access to Critical Breakthrough Products Act CDC Arthritis Program - Appropriations Congressionally Directed Medical Research Program - Appropriations ATPCs Arthritis Research Medicaid H.R. 4299, "the Protecting Patient Access to Cancer and Complex Therapies Act"
Client expense: $75,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2026 · third_quarter · Health Issues
Issues related to legislation relating to the 340B drug discount program. Also, legislation relating to Medicare physician payments, including H.R. 4299. Issues relating to GLOBE/GUARD
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to access and physician reimbursement under Medicare Part B, including H.R. 879 - Medicare Patient Access and Practice Stabilization Act; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025 Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R. 2484- Seniors' Access to Critical Medications Act of 2025. Issues related to prior authorization. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to stark regulation of in office dispensing of Part D drugs. Issues related to the Provider Reimbursement Stability Act of 2026 (H.R.8163). Issues related to the Patients First Act of 2026 (H.R.9693)
Client expense: Not reported · Firm income: $90,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex.
Client expense: Not reported · Firm income: $20,000
Government targets: SENATE
2026 · third_quarter · Pharmacy
Issues related to drug pricing. H.R.4299/S.__ - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $30,000
Government targets: SENATE
2026 · third_quarter · Pharmacy
Issues related to drug pricing. H.R.4299/S.__ - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $30,000
Government targets: SENATE
2026 · third_quarter · Pharmacy
Issues related to drug pricing. H.R.4299/S.__ - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $30,000
Government targets: SENATE
2026 · third_quarter · Pharmacy
Issues related to drug pricing. H.R.4299/S.__ - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $50,000
Government targets: SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
H.R. 2484, Seniors Access to Critical Medications Act of 2025 (Support: Allows medically integrated physician dispensing flexibilities); H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025 (Support: Increases provider reimbursement in the Physician Fee Schedule); H.R. 2120, ROCR Value Based Program Act (Support: Modifies Medicare payment system for radiation oncology services); S. 1816 H.R. 3514, Improving Seniors' Timely Access to Care Act of 2025 (Support: Streamlines prior authorization process); Medicare Physician Payment; Site Neutral Payment Reform; CY2026 Medicare Physician Fee Schedule Proposed Rule; H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (Support: Provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation); PBM Transparency; Emergency Preparedness.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to fertility treatment, oncology and coverage, including: H.R. 8119, the HOPE with Fertility Services Act; H.R. 1670 and S. 797, the Family Building FEHB Fairness Act; H.R. 220, the Veterans Infertility Treatment Act; H.R. 7841, Warrior Infertility Act; H.R. 6797, the Bipartisan IVF for Military Families Act; and H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: $260,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.3251/S 4440 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement -Update CMS Long stay antipsychotic Quality measure -Update FDA Antipsychotic black box warning -Funding for NIH (HR 9260) -PASTEUR Act (HR 7352/S 4975) -Biosimilar Access and Affordability Act (HR10628/S5571) -CMS Fixed Dose Combination Therapies proposed policy -OMB Proposed Uniform Guidance on Federal Grantmaking (HR 6500) -Alzheimer's Early Detection Act (HR 9823) -CMS reporting requirements for Medicare Prescription Payment Program (HR 9260) -CMS Trans Catheter Aortic Valve Replacement NCD proposal
Client expense: $65,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Pharmacy
Prescription drug pricing policy. H.R.1492 - Ensuring Pathways to Innovation Cures (EPIC) Act. ORPHAN Cures Act. MINI Act. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act. H.R.7391 - Community Health Center Drug Pricing Protection Act. H.R.5509 - Safe Step Act. Clinical Trial Modernization Act. Essential medicines/Buy American. Issues related to the 340B Drug Pricing Program. International Reference Pricing/Most Favored Nation.
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Rare Disease Issues. H.R.4299: Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES
2026 · third_quarter · Medicare/Medicaid
H.R. 3514/S. 1816: Improving Seniors' Timely Access to Care Act of 2025 - requires Medicare Advantage plans to implement electronic prior authorization, increase transparency, protect enrollees, and adhere to new response timeframes to improve timely access to care. H.R. 2433: Reducing Medically Unnecessary Delays in Care Act - mandates that prior authorization decisions under Medicare be made by qualified physicians, based on medical necessity and evidence-based standards, with transparency and input from practicing physicians. H.R. 9693, Patients First Act of 2026 would finally make structural changes needed to prevent cuts and create a payment system that helps ensure physicians can keep their doors open and provide seniors with quality, value-based healthcare. S. 1640/H.R. 879: Medicare Patient Access and Practice Stabilization Act of 2025 - This bill increases certain payment adjustments under the Medicare physician fee schedule for services furnished between April 1, 2025, and January 1, 2026. H.R. 8163/S. 5180: Provider Reimbursement Stability Act, to amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program. H.R. 8622: Medicare Physician Data-driven Performance Payment System Act to amend title XVIII of the Social Security Act to transform the Merit-based Incentive Payment System into the Data-driven Performance Payment System under the Medicare physician fee schedule H.R. 6160: Strengthening Medicare for Patients and Providers Act to modify certain adjustments to payment amounts under the Medicare physician fee schedule S. 1460/H.R. 786: Preserving Patient Access to Accountable Care Act - extends Medicare incentive payments for alternative payment models to 2027, with a new rate of 3.53 percent, to promote continued participation and improve healthcare efficiency. H.R. 2120/S. 1031: ROCR Value Based Program Act - establishes a new payment program for radiation oncology services, focusing on stable payments, quality care, and patient access, while exempting it from budget neutrality adjustments. H.R. 4559: Prompt and Fair Pay Act - to establish payment parity between Medicare Advantage and fee-for-service Medicare, and to establish prompt payment requirements under Medicare Advantage. H.R. 2484: Seniors' Access to Critical Medications Act of 2025 - establishes an exception to the physician self-referral prohibition for certain outpatient drugs under Medicare, mandates a study on drug dispensing practices, and reduces the Medicare improvement fund by $18 million. H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act - provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation. H.R. 4206/S. 1261: CONNECT for Health Act - expands access to telehealth services under Medicare H.R. 5081/S. 2709: Telehealth Modernization Act - to extend certain telehealth flexibilities under the Medicare program. H.R. 4752/S. 2760: Reducing Hereditary Cancer Act - to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation. H.R. 8500: Timely Access to Coverage Decisions Act of 2026: To amend title XVIII of the Social Security Act to ensure timely review of local coverage determination requests under the Medicare program. H.R. 4331, Access to Claims Data Act: To require the Secretary of Health and Human Services to establish a process to expand access to claims data under certain Federal health plans in order to facilitate research and quality improvement.
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Appropriations funding for the CDC, OMH, lupus and the DoD CDMRP; NIH funding, Medicare Part D, step therapy, prior authorization, HR 4299 the Protecting Patient Access to Therapies Act
Client expense: $6,700 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Health care priorities of ACCC: 1) Prior authorization (Including: Improving Seniors Timely Access to Care Act of 2025 (S.1816/ H.R. 3514); 2) Oncology drug and medical supply shortages; 4) Financial toxicity for cancer patients; 5) Drug Pricing: Inflation Reduction Act implementation, Senate Finance Minority Drug Pricing RFI, and the Protecting Patient Access to Cancer and Complex Therapies Act (H.R.4299); 6) Reducing Physician Payment Reimbursement Cuts; 7) Healthcare Workforce improvement; 8) H.R. 6718 the Professional Student Degree Act (to endorse, not yet communicated to sponsors office); 9) Preserve Medicaid coverage for caregivers and other beneficiaries (mitigate potential impact of One Big Beautiful Bill Act (OBBBA) implementation on their coverage); 10) Safe Step Act (H.R. 5509/S. 2903); 11) Radiation Oncology Case Rate (ROCR) Value Based Program Act(H.R. 2120/S.1031); 12) Maintain and promote access to coverage (including renewal of ACA subsidies and mitigating impact of Medicaid changes in OBBBA); 13) Access to Genetic Counselor Services Act (S. 3607/H.R. 6280); 15) Support appropriations for strong NIH funding; 16) Planning and coalition work for advocacy on supportive cancer care, including efforts to get language in Senate appropriations bill relating to benefits and costs of such care; 17) Clinical Trial Modernization Act (HR 3521/S. 4440); 18) Proposals to reform the 340B program (Senate); 19) Request that Congressional appropriating committees oppose the implementation of the Office of Management and Budget (OMB) Uniform Guidance.
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: Not reported
2026 · third_quarter · Health Issues
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Client expense: Not reported · Firm income: Not reported
2026 · second_quarter · Health Issues
-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
HR 4299 - The Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office